Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 10/20 | 0.81 |
| ▸ | CDK2 | P24941 | 10/20 | 0.81 |
| ▸ | CDK5 | Q00535 | 11/20 | 0.79 |
| ▸ | CDK5R1 | Q15078 | 11/20 | 0.79 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | GSK3A | P49840 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248181 | 0.90 | CDK2 (1.00) | CCNA2CDK2CDK5CDK5R1CCNE1 | |
| SCHEMBL20142387 | 0.89 | CCNA2 (0.81) | CCNA2CDK2CDK5CDK5R1CCNE1 | |
| SCHEMBL7756972 | 0.89 | CCNA2 (0.81) | CCNA2CDK2CDK5CDK5R1CCNE1 | |
| SCHEMBL7757586 | 0.87 | CCNA2 (0.82) | CCNA2CDK2CDK5CDK5R1NPC1 | |
| SCHEMBL4395888 | 0.87 | CDK5 (0.80) | CCNA2CDK2CDK5CDK5R1CCNE1 | |
| SCHEMBL4402949 | 0.86 | CDK5 (0.70) | CCNA2CDK2CDK5CDK5R1NPC1 | |
| SCHEMBL25609793 | 0.86 | CDK5 (0.74) | CCNA2CDK2CDK5CDK5R1CCNE1 | |
| SCHEMBL20142395 | 0.86 | CCNA2 (0.77) | CCNA2CDK2CDK5CDK5R1CCNE1 | |
| SCHEMBL4398263 | 0.85 | CDK5 (0.72) | CCNA2CDK2CDK5CDK5R1NPC1 | |
| SCHEMBL20142858 | 0.83 | CCNA2 (0.72) | CCNA2CDK2CDK5CDK5R1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829014-B2 | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2007393-B1 | THIAZOLE AND THIOPHENE ANALOGUES, AND THEIR USE IN TREATING AUTOIMMUNE DISEASES AND CANCERS | UNIV LOUISIANA STATE (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20120283268-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | GIORDANO ANTHONY (US) | 2012-11-08 | — | — | US | disclosed |
| US-8217037-B2 | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2012-07-10 | — | — | US | disclosed |
| US-20090306073-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | B.V. PATEL PHARMACEUTICAL EDUCATION & RESEARCH DEVELOPMENT (PERD) CENTRE (IN) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306073-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | TPMT, TST, SSB | CCNA2 2213/4885CDK2 409/4885CDK5 732/4885 |
| US-20120283268-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | TPMT, TST, SSB | CCNA2 2213/4885CDK2 409/4885CDK5 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.